Although there have been a number of new value calculators created recently, UnitedHealthcare does not plan to use any just now. Instead, it will continue covering regimens recommended by the National Comprehensive Cancer Network and in a few years the company will use data from its prior authorization tool to analyze performance of regimens, explained Lee Newcomer, MD, MHA, senior vice president, Oncology, Genetics and Women's Health, UnitedHealthcare.
Although there have been a number of new value calculators created recently, UnitedHealthcare does not plan to use any just now. Instead, it will continue covering regimens recommended by the National Comprehensive Cancer Network and in a few years the company will use data from its prior authorization tool to analyze performance of regimens, explained Lee Newcomer, MD, MHA, senior vice president, Oncology, Genetics and Women’s Health, UnitedHealthcare.
Transcript (slightly modified for readability)
Does UnitedHealthcare have plans to leverage any of the value calculators that have been created?
No. We're still saying, as always, that if you're using a regimen recomended by the National Comprehensive Cancer Network (NCCN), we will cover it. There may come a day, as our prior authorization tool becomes to show us performance of those regimens, we'll be displaying the data on the tool about how each regimen is doing with UnitedHealthcare patients. So if we find regimens that are causing more toxicity, or that are so expensive without showing better results, then eventually we may winnow those out. But that is at least 3 years in the future.
How is UnitedHealthcare expecting to integrate new immuno-oncology agents into its payment program?
No differently than any other drug. If the evidence is there, it will be covered. Again, we will rely on the NCCN to help us with that determination.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More